USPTO serial 79396229
R
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 16, 2025
- Examiner
- SMITH, CAROLINE P
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with R?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Cheryl L. Burbach
Cheryl L. Burbach Erise IP, P.A.7015 College Blvd.Suite 700Overland Park, KS 66211Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical, biological, and pharmaceutical preparations for the treatment of viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock, for the treatment of viral infections, bacterial infections, cancer, viral, bacterial, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; medical, biological, and pharmaceutical preparations for preventing and treating viral, bacterial, and yeast infections; veterinary preparations for pets, cattle, livestock, for preventing and treating viral, bacterial, and yeast infections; medical, biological, and pharmaceutical preparations for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; veterinary preparations for pets, cattle, livestock for preventing and treating cancer, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines; sanitary preparations for medical purposes; dietary supplements and dietetic preparations adapted for medical purposes; dietetic foods adapted for medical use; diagnostic preparations for medical purposes; diagnostic chemical reagents for medical use; clinical medical reagents | ACTIVE | — |
| 042 | Biological research; clinical research in the field of age-related diseases and cancer; medical research; research and development services in the field of pharmaceutical preparations; pharmaceutical products development; pharmaceutical product evaluation; research and development in the field of microorganisms and cells; research on the subject of pharmaceuticals; testing of pharmaceuticals; laboratory research services relating to pharmaceutical product development; development of gene-based medicines; drug discovery services; scientific research in the nature of conducting clinical trials for others relating to pharmaceutical products; scientific laboratory services; laboratory research services relating to pharmaceuticals; scientific risk assessment being consultation in the field of health risk assessment, namely, prediction and assessment of health risks to public and private agencies, facilities, individuals and locations following an accidental or terrorist caused release of chemical, biological, radiological or nuclear materials; consulting services in the field of pharmaceutical research; testing of pharmaceuticals being services for assessing the efficiency of pharmaceuticals; pharmaceutical toxicity testing for research purposes; pharmaceutical toxicity analysis services for scientific research purposes; computer services, namely, remote management of the information technology (IT) systems of others for the pharmaceutical and healthcare industries; conducting early evaluations in the field of new pharmaceuticals; providing information about scientific research, namely, the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; chemical research and analysis services; medical and pharmacological research services; scientific services, namely, scientific research in the field of genetics; scientific research for medical purposes in the field of age-related diseases and cancer; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of genetics; genetic mapping for scientific purposes; DNA screening for scientific research purposes; providing scientific research information in the field of pharmaceuticals for the treatment of medical disorders; technical research in the field of pharmaceutical studies; veterinary research; design and development of computer software relating to the medical field; design and development of computer software relating to healthcare; computer programming in the medical field; scientific computer programming services; providing temporary use of non-downloadable software for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data; providing temporary use of on-line non-downloadable computer programs on data networks using artificial intelligence (AI) for use in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; platform as a service (PAAS) featuring computer software platforms using artificial intelligence (AI) for use in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) services featuring software for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) featuring software using artificial intelligence (AI) for capturing, storing, processing, evaluating and reproducing medical and pharmaceutical data in the life sciences research field, pharmaceutical research, medical research, drug discovery and development; software as a service (SaaS) featuring software using artificial intelligence (AI) for analysis of self-assessment of illnesses; software as a service (SaaS) featuring software using artificial intelligence (AI) for machine learning in the field of healthcare; software as a service (SaaS) featuring health monitoring software; software as a service (SaaS) featuring software for analyzing biological genetic data; technology consultation in the field of artificial intelligence (AI); research in the field of artificial intelligence (AI) | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Rejuvenate Biomed NV
- Other trademarks owned by Rejuvenate Biomed NV
- Other trademarks owned by Rejuvenate Biomed NV
- Other trademarks owned by Rejuvenate Biomed NV
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named R
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 23, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 23, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 23, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 23, 2026 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 23, 2026 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 16, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 28, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 27, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Dec 16, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 22, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Nov 14, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 22, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 22, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 16, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 16, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 29, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 29, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 23, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 20, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 1, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 1, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 1, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 28, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 23, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Nov 8, 2024 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Nov 5, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 5, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 30, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 29, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 25, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 3, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 3, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 23, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |